Pharmsville팜스빌

Pharmsville's revenue has fallen sharply for several years and it is loss-making at the operating line, though its net profit in 2026 is far higher than its operating result.

Pharmsville, a Korean health-food maker listed on KOSDAQ, reported trailing revenue of ₩11.2B... wait, figures are in won: trailing twelve-month revenue of ₩11.2B is down from ₩39.0B in 2021, with an operating loss of ₩0.7B over the same period. The shares closed at ₩3,525 on 2026-10-16, about 9% lower over one year, with a market value of ₩28.0B and a P/B of 0.4.

What stands out

• Revenue has declined every year shown, from ₩39.0B in 2021 to ₩12.7B in 2025, and the trailing figure to H1 2026 is ₩11.2B.
• Operating income has been negative for 2024, 2025 and the trailing period, with a trailing operating margin of -6.1%.
• Trailing net income of ₩3.0B is far above operating income, and the filings do not explain the gap in the data provided; net margin of 26.7% should not be read as core profitability.
• The company reports cash of ₩4.9B, no borrowings, and trailing free cash flow of ₩1.5B, with liabilities at 2.5% of equity.
• The DCF base value is ₩622 against a ₩3,525 close, and the bear and bull values are ₩407 and ₩1,033; the data does not show how these inputs were chosen, and the model is not a forecast.
• Foreign ownership is 0.9% and has been unchanged over 60 days; recent 20-day flows show net selling by foreign and retail investors.

What to watch

• The amended half-year and quarterly reports filed on 2026-08-20 may change the figures; check the revised numbers in the filings.
• Whether operating losses narrow, given the revenue decline and the value-up plan filed on 2026-03-26; the data does not give targets.
• The data contains no news headlines, so any change in business direction or risks beyond the filings is not visible here.